Values of Fluorodeoxyglucose-Pet Versus Fluorodeoxyglucose-Pet/Computed Tomography in Differentiated Thyroid Carcinoma with Radioiodine-Negative Whole Body Scan - A Meta Analysis

Meng-jie Dong,Kui Zhao,Ling-xiang Ruan,Zhen-feng Liu,Guo-lin Wang,Shu-ye Yang
2009-01-01
Abstract:1776 Objectives To evaluate the diagnosticaccuracy of FDG-PET and FDG-PET/CT in the detection of recurrent or metastatic differentiated thyroid carcinoma (DTC)unidentified by radioiodine whole-body scintigraphy (WBS). Methods Twenty-five studies (involving a total of 789 patients) published from January 1990 to September 2008 were reviewed. These studies evaluated the role of FDG PET and FDG PET/CT in the detection of recurrent or metastatic DTC after radioiodine whole-body scintigraphy failed to detect. Systematic methods were used to identify, select, and evaluate the methodological quality of the studies as well as to summarize the overall findings of sensitivity, specificity. Results Seventeen studies presenting 571 patients who had recurrent or metastatic DTC and radioiodine-negative whole body scan were collected, and the overall patient-based sensitivity and specificity of FDG-PET were 0.835 (95% CI 0.791-0.873), and was 0.843 (95% CI 0.791-0.886), respectively. The pooled sensitivity, specificity in the DTC patients who present with elevated serum thyroglobulin and negative 131I scan were 0.885 (95%CI 0.828-0.929) and 0.847 (95%CI 0.715-0.934), respectively. In the 6 studies where the 165 patients diagnosed by 18F-FDG PET/CT, and pooled sensitivity and specificity were 0.935 (95%CI 0.870-0.973) and 0.839 (95%CI 0.723-0.920), respectively. Conclusions FDG-PET/CT can be a high valuable tool for detecting DTC recurrence or metastases in radioiodine-negative patients.
What problem does this paper attempt to address?